FindMyKOL

Michelle Kim, MD

Enriched profile

Professor (University of Michigan) · University of Michigan

ORCIDNone on fileNPI↗
✓ Itemized profile
Region🇺🇸 Ann Arbor, MI · Midwest · United StatesSpecialtyRadiation OncologyFocusNeuro-Oncology / Glioma+3
Active KOLFindMyKOL type: RegionalLatest publicationNone indexedOnline presenceNone verifiedPayments2021–2025NIH funding2023–2026Why? →

Michelle Kim is Professor (University of Michigan) at University of Michigan. ClinicalTrials.gov lists 7 registered studies with this person as an investigator.

Data verified 4 Nov 2026

Overview

Updated 4 Nov 2026

Michelle Kim, M.D., is Professor (University of Michigan). It also documents an investigator role on 7 registered clinical trials, industry payments reported by 3 companies, 1 NIH-funded awards (2023–2026).

  • Top research focus: Neuro-Oncology / Glioma
  • 7 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 3 companies

Generated from the cited public record · current as of 4 Nov 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Neuro-Oncology / Glioma4 trialsNeoplasm Metastasis2 trialsBrain Neoplasms2 trialsBreast Cancer1 trialLung Cancer (NSCLC/SCLC)1 trialKidney Cancer / RCC1 trialMelanoma1 trialCarcinoma, Small Cell1 trialGlioma1 trial

Research focus

OpenAlex concept fingerprint
Neuro-Oncology / GliomaBrain NeoplasmsGliomaNeoplasm Metastasis

Drugs & molecules

across trials, industry payments and publications
FluciclovineClinical trials—Industry payments2Publications—

Works with

trial sponsors and companies reporting payments
University of Michigan Rogel Cancer CenterClinical trials3Industry payments—Blue Earth Diagnostics LimitedClinical trials—Industry payments2Telix PharmaceuticalsClinical trials—Industry payments2Canadian Cancer Trials GroupClinical trials1Industry payments—ECOG-ACRIN Cancer Research GroupClinical trials1Industry payments—EpicentRx, Inc.Clinical trials1Industry payments—Mevion_Medical_Systems_IncClinical trials—Industry payments1NRG OncologyClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓

Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →

Clinical & industry

trials, payments and federal funding
7clinical trials

Investigator role on registered studies.

View trials ↓
3companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 2023–2026

Federally funded research awards.

View funding ↓

Public positions

sourced statements on record
  • Co-Chair

    University of Michigan Rogel Cancer Center Neuro-Oncology Clinical Research Team

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →amportal.astro.org ↗

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 4 Nov 2026

Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:

All 7 trial records: search, sort and filter.Explore →

Industry payments

Updated 4 Nov 2026

3 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 4 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    52.2%
    Corticosteroid52.2%
    Dexamethasone100%
    Part D<11 patients

  • Nervous system

    47.8%
    N-methyl-D-aspartate Receptor Antagonist47.8%
    Memantine Hcl100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 4 Nov 2026

1 NIH research award on record, funded 2023–2026 per NIH RePORTER. The latest:

All 6 award records: search, sort and filter.Explore →

Publications

None on file yet. We only list publications we can confidently match to this person. Why? →

Background & recognition

Updated 4 Nov 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Editorial & leadership roles

journal and society appointments
  • Member

    NCCN CNS Guidelines Committee

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →amportal.astro.org ↗
  • Board Member

    Neuro-Oncology Editorial Board

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →amportal.astro.org ↗
  • CNS Section Editor

    Red Journal

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →amportal.astro.org ↗
  • ASTRO Annual Meeting Education Committee (current)
    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →amportal.astro.org ↗

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.